ProKidney Corp. PROK
1.11 USD -0.04 (-3.48%)
At closeNov 10, 2026, 4:26 PM EST
1.11 0.00 0.00%
After hours · Nov 10, 4:26 PM ET
1.07 Day range 1.17
0.87 52-week range 2.88
- YTD
- -50.45%
- 1 year
- -58.89%
News
benzinga.com ProKidney Corp. Enters $200 Million At-The-Market Offering Agreement With Jefferies On October 29, 2026, ProKidney Corp. (the "Company") entered into an Open Market Sale AgreementSM (the "Sales Agreement") with Jefferies LLC (the "Sales Agent"), pursuant to which the Company may
benzinga.com Citigroup Maintains Buy on ProKidney, Lowers Price Target to $8 Citigroup analyst Yigal Nochomovitz maintains ProKidney (NASDAQ:PROK) with a Buy and lowers the price target from $10 to $8.
marketbeat.com ProKidney Targets Q2 2027 Phase III Readout as Rilparencel Enrollment Surpasses 500 ProKidney NASDAQ: PROK said it remains on track to report top-line results from the interim analysis of its Phase III PROACT 1 study in the second quarter of 2027, following stronger-than-expected…
seekingalpha.com ProKidney Corp. (PROK) Discusses Rilparencel Mechanism and Role in Advanced Chronic Kidney Disease Transcript ProKidney Corp. (PROK) Discusses Rilparencel Mechanism and Role in Advanced Chronic Kidney Disease Transcript
globenewswire.com ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney…
globenewswire.com ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026 Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencel One clinical…
globenewswire.com ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026 WINSTON-SALEM, N.C., Oct. 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney…
defenseworld.net Critical Analysis: Pyxis Oncology (NASDAQ:PYXS) vs. ProKidney (NASDAQ:PROK) ProKidney (NASDAQ: PROK - Get Free Report) and Pyxis Oncology (NASDAQ: PYXS - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two…
marketwatch.com 20 stocks likely to lose money even if the bull market continues Certain stocks are such poor bets that they are likely to lose ground even in bull markets.
seekingalpha.com ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade) ProKidney Corp. is a single-asset biotech with a dwindling cash position and an unproven lead therapy, rilparencel. Phase 2 data for rilparencel is weak, with confounding factors and no robust…
zacks.com ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates ProKidney Corp. (PROK) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.
benzinga.com ProKidney Q2 EPS $(0.15) Misses $(0.14) Estimate, Sales $150.000K Beat $149.000K Estimate ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.14) by 7.14 percent. This is a 15.38 percent decrease over losses of $(0.13)…
benzinga.com AEVEX, Abivax, Watts Water Technologies And Other Big Stocks Moving Higher On Tuesday Stocks up, Dow Jones +100 points. AEVEX Corp shares rose 11.8% on $50m Air Force contract. Other big gainers: ABVX +34.2%, ESBA +20.9%, AVAV +20.4%, AIRJ +17.4%, FCEL +14%, UMAC +11.1%, HSAI +10.7%,…
benzinga.com Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrollment of first patient in phase 3 trial.
globenewswire.com ProKidney Appoints Kenneth Locke as Chief Technical Officer Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the…- benzinga.com HC Wainwright & Co. Reiterates Buy on ProKidney, Maintains $12 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates ProKidney (NASDAQ:PROK) with a Buy and maintains $12 price target.
zacks.com ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates ProKidney Corp. (PROK) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.- benzinga.com ProKidney Q1 EPS $(0.14), Inline, Sales $226.000K Beat $143.667K Estimate ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. This is a 7.69 percent decrease over losses of $(0.13) per share from the same period…
globenewswire.com ProKidney Reports First Quarter 2026 Financial Results and Business Highlights WINSTON-SALEM, N.C., May 15, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney…
defenseworld.net Head-To-Head Contrast: ProKidney (NASDAQ:PROK) & Phio Pharmaceuticals (NASDAQ:PHIO) Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and ProKidney (NASDAQ: PROK - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two…
globenewswire.com ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney…
defenseworld.net ProKidney Corp. (NASDAQ:PROK) Given Consensus Recommendation of “Moderate Buy” by Brokerages Shares of ProKidney Corp. (NASDAQ: PROK - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight ratings firms that are presently covering the firm, MarketBeat reports. Two…
benzinga.com ProKidney Q4 EPS $(0.14) Misses $(0.11) Estimate, Sales $225.000K Beat $83.333K Estimate ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.11) by 23.89 percent. This is a 12.5 percent increase over losses of $(0.16)…
defenseworld.net ProKidney (PROK) Projected to Post Earnings on Monday ProKidney (NASDAQ: PROK - Get Free Report) will likely be releasing its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect the company to announce earnings of ($0.16) per…
seekingalpha.com ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably PROK's main value driver is Rilparencel, which is now in a pivotal trial called PROACT 1. The FDA also accepted using eGFR slope analysis for evaluating its potential accelerated approval. PROK…
seekingalpha.com ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
globenewswire.com ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com This MYR Group Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - benzinga.com HC Wainwright & Co. Initiates Coverage On ProKidney with Buy Rating, Announces Price Target of $12 HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on ProKidney (NASDAQ:PROK) with a Buy rating and announces Price Target of $12.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today's Session 
defenseworld.net ProKidney Corp. (NASDAQ:PROK) Receives Average Rating of “Hold” from Analysts Shares of ProKidney Corp. (NASDAQ: PROK - Get Free Report) have been given a consensus recommendation of "Hold" by the six research firms that are currently covering the company, MarketBeat reports.…
benzinga.com ProKidney Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $217.000K Beat $44.250K Estimate ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 13.04 percent. This is a 14.29 percent increase over losses of $(0.14)…
benzinga.com ProKidney To Present LAte-Breaking Poster On Phase 2 REGEN-007 Trial Results At American Society of Nephrology's Kidney Week WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic…
benzinga.com ProKidney Corp. Signs New $19.1M Agreement To Sell Greensboro, NC Property After Prior Deal Termination As previously disclosed, on May 8, 2025, ProKidney Corp. (the "Company"), through its wholly owned subsidiary, ProKidney Acquisition Company, LLC ("Acquisition Sub"), entered into a purchase and sale…
benzinga.com SPAC King Chamath Palihapitiya Tells Retail Investors To Stay Away From His New SPAC Chamath Palihapitiya is back with another SPAC. This time he's telling retail investors to stay away. Here's why.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Chamath Palihapitiya Returns To SPACs: Past 18 Deals, Investments Average Loss Of 14% Chamath Palihapitiya is back with a new SPAC. Many investors will remember past SPACs the investor was involved with and the poor performance track record.
benzinga.com ProKidney Q2 EPS $(0.13) Beats $(0.15) Estimate, Sales $221.000K ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 18.75 percent increase over losses of $(0.16)…- benzinga.com Watching ProKidney Corp; Zacks Upgrades Stock To Strong Buy https://www.zacks.com/stock/news/2589077/prokidney-cp-prok-upgraded-to-strong-buy-what-does-it-mean-for-the-stock
- benzinga.com UBS Maintains Buy on ProKidney, Raises Price Target to $8 UBS analyst Eliana Merle maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $4 to $8.
benzinga.com Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - benzinga.com ProKidney Confirms Alignment With FDA On Accelerated Approval Pathway For Rilparencel FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT 1…
- benzinga.com Guggenheim Maintains Buy on ProKidney, Raises Price Target to $7 Guggenheim analyst Vamil Divan maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $6 to $7.
- benzinga.com Guggenheim Maintains Buy on ProKidney, Raises Price Target to $7 Guggenheim analyst Vamil Divan maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $6 to $7.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com AZZ Posts Better-Than-Expected Earnings, Joins MP Materials, WK Kellogg And Other Big Stocks Moving Higher On Thursday 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Why WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket - benzinga.com Citigroup Maintains Buy on ProKidney, Raises Price Target to $9 Citigroup analyst Yigal Nochomovitz maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $6 to $9.